Lexeo's PKP2 cardiomyopathy gene therapy adds RMAT status

Lexeo Therapeutics has received FDA RMAT designation for LX2020, a gene therapy targeting PKP2-associated arrhythmogenic cardiomyopathy, based on interim Phase I/II clinical data showing promising protein expression restoration and arrhythmia improvements.

This Wire brief sits within Fusion42's coverage of Biotech, and 3 sources have reported it between 6 Aug 2026 and 11 Aug 2026.